No Data
Ionis to Present at 43rd Annual J.P. Morgan Healthcare Conference
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Insider Trades: Walmart, Teva Among Notable Names This Week
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 31%?